98%
921
2 minutes
20
Isocitrate dehydrogenase wild-type (IDHwt) diffuse astrocytomas feature highly infiltrative patterns, such as a gliomatosis cerebri growth pattern with widespread involvement. Among these tumors, localized IDHwt histologically diffuse astrocytomas are rarer than the infiltrative type. The aim of this study was to assess and describe the clinical, radiographic, histopathological, and molecular characteristics of this rare type of IDHwt histologically diffuse astrocytomas and thereby provide more information on how its features affect clinical prognoses and outcomes. We retrospectively analyzed the records of five patients with localized IDHwt histologically diffuse astrocytomas between July 2017 and January 2020. All patients were female, and their mean age at the time of the initial treatment was 55.0 years. All patients had focal disease that did not include gliomatosis cerebri or multifocal disease. All patients received a histopathological diagnosis of diffuse astrocytomas at the time of the initial treatment. For recurrent tumors, second surgeries were performed at a mean of 12.4 months after the initial surgery. A histopathological diagnosis of glioblastoma was made in four patients and one of gliosarcoma in one patient. The initial status of IDH1, IDH2, H3F3A, HIST1H3B, and BRAF was "wild-type" in all patients. TERT promoter mutations (C250T or C228T) were detected in four patients. No tumors harbored a 1p/19q codeletion, EGFR amplification, or chromosome 7 gain/10 loss (+ 7/ - 10). We assessed clinical cases of localized IDHwt histologically diffuse astrocytomas that resulted in malignant recurrence and a poor clinical prognosis similar to that of glioblastomas. Our case series suggests that even in patients with histologically diffuse astrocytomas and those who present with radiographic imaging findings suggestive of a localized tumor mass, physicians should consider the possibility of IDHwt histologically diffuse astrocytomas.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842655 | PMC |
http://dx.doi.org/10.1038/s41598-022-25928-2 | DOI Listing |
medRxiv
August 2025
Neurosurgical Oncology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1414.
Background: LB100 is a protein phosphatase 2A (PP2A) inhibitor. Glioma models show inhibition of PP2A by LB100 causes cell death. Whether LB100 crosses the human blood brain barrier (BBB) is unknown.
View Article and Find Full Text PDFNeuro Oncol
August 2025
Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Background: This study explored MRI characteristics at the time of tumor progression to study pathologically-confirmed MT in IDHm 1p/19q-intact astrocytomas (IDHm-A) and IDHm 1p/19q-co-deleted oligodendrogliomas (IDHm-O).
Methods: N=64 patients with initial pathological grade 2 IDH-mutant glioma diagnosis who underwent repeated tissue sampling and were classified as pathologically-confirmed MT (n=35) or non-MT (n=29) with available pre-surgical anatomical (n=64), diffusion-weighted (n=61), and dynamic susceptibility contrast perfusion MRI (n=53) were retrospectively studied. Measurable contrast enhancement (>1000mm3), tumor volume, tumor growth rate, sphericity, median apparent diffusion coefficient (ADC), and normalized relative cerebral blood volume (nrCBV) were compared between MT vs.
Pharmaceutics
August 2025
Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 3 Rokietnicka, 60-806 Poznań, Poland.
: Adult-type diffuse gliomas, including astrocytoma and glioblastoma multiforme (GBM), are brain tumors with a very poor prognosis. While current treatment options for glioma patients are not providing satisfactory outcomes, research indicates that natural compounds could serve as alternative treatments. However, their low bioavailability requires nanotechnology solutions, such as liposomes.
View Article and Find Full Text PDFBMC Med Imaging
August 2025
Department of Radiology, The First Affiliated Hospital, Fujian Medical University, 20 Cha-Zhong Road, Fuzhou, Fujian, 350005, P.R. China.
Purpose: The differential diagnosis of primary central nervous system lymphoma (PCNSL) and atypical glioblastoma (aGBM) exhibiting homogeneous enhancement and negligible necrosis poses a significant challenge for conventional MRI. The study aims to investigate diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) MRI, and contrast agent (CA) preload dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) to differentiate aGBM and PCNSL.
Materials And Methods: This retrospective study analyzed 27 patients with aGBM (solid enhancement without visible necrosis) and 105 patients with PCNSL, all undergoing preoperative DWI, DCE-MRI, and CA preload DSC-PWI.
Cureus
July 2025
Pathology, Akhtar Saeed Medical & Dental College, Rawalpindi, PAK.
Despite their biological and molecular heterogeneity, pediatric-type diffuse low-grade gliomas exhibit significantly different prognostic outcomes compared to their adult-type counterparts. Accurate diagnosis is essential to avoid aggressive overtreatment and to enable exploration of relevant molecular targets for personalized therapy. This review provides a comprehensive overview of the epidemiology, clinical presentation, radiologic findings, histopathologic features, and key molecular events characterizing the newly defined WHO subgroup "pediatric-type diffuse low-grade gliomas.
View Article and Find Full Text PDF